

# ALKEM Laboratories

Estimate change	↑
TP change	↑
Rating change	↔

**CMP: INR5,452      TP: INR5,840 (+7%)      Neutral**

## Strong finish; softer road ahead

**Domestic revival and US momentum intact; opex limits the earnings upgrade cycle**

Bloomberg	ALKEM IN
Equity Shares (m)	120
M.Cap.(INRb)/(USDb)	651.8 / 6.8
52-Week Range (INR)	5934 / 4716
1, 6, 12 Rel. Per (%)	3/5/7
12M Avg Val (INR M)	880

### Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	147.1	165.4	183.8
EBITDA	30.1	33.6	38.1
Adjusted PAT	25.5	22.3	25.1
EBIT Margin (%)	17.8	17.5	17.9
Adj EPS (INR)	213.4	186.1	210.1
EPS Gr. (%)	17.8	-12.8	12.9
BV/Sh. (INR)	1,156	1,277	1,422

### Ratios

Net D-E	0.0	0.0	0.0
RoE (%)	19.8	15.3	15.6
RoCE (%)	18.0	14.8	15.1
Payout (%)	30.8	35.0	31.0

### Valuations

P/E (x)	25.5	29.3	26.0
EV/EBITDA (x)	21.8	19.5	16.9
Div. Yield (%)	0.9	1.0	1.0
FCF Yield (%)	2.3	0.8	2.5
EV/Sales (x)	4.4	4.0	3.5

### Shareholding Pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	51.2	51.2	55.1
DII	21.4	21.5	19.4
FII	10.2	10.0	9.4
Others	17.3	17.3	16.1

FII includes depository receipts

- Alkem Laboratories (ALKEM) delivered a better-than-expected financial performance with a 4%, 6%, and 16% beat on revenue, EBITDA, and PAT for 4QFY26. Strong traction in the exports segment and higher other income led to superior performance for the quarter.
- ALKEM exhibited 100bp YoY outperformance to the industry growth in the domestic formulation (DF) segment. Revival in Acute therapies and sustained growth momentum in chronic therapies led to better-than-industry growth for ALKEM. The trade generics segment is in a gradual recovery mode.
- The US business segment sustained the sales momentum on the back of new launches and increased volume off-take. The niche product launches are expected to sustain the growth prospects in FY27 as well.
- Broad-based growth across markets led to 24%/27% YoY growth in the Non-US export segment in 4QFY26/FY26.
- We raise our earnings estimate by 3%/5% for FY27/FY28, factoring in 1) limited competition product pipeline for the US market, 2) enhanced efforts to benefit from Semaglutide opportunities, and 3) a reduction in effective tax rate estimate. We value ALKEM at 28x 12M forward earnings to arrive at our TP of INR5,840.
- The company ended FY26 on a strong note with 13.5%, 20%, and 18% YoY growth in revenue, EBITDA, and PAT, respectively. Having said this, we expect moderation in the earnings growth trajectory over the next two years due to operational costs related to biosimilars for the US market, efforts towards improving growth prospects of the Occlutech business, and a step-up in tax rate from 18% in FY26 to 27-28% in FY27.
- Considering stable earnings over FY26-28 and valuation (29x FY27E/26x FY28E earnings), we reiterate our Neutral rating on the stock.

### Segmental mix benefit offset by higher operational costs YoY

- ALKEM's 4QFY26 revenues grew 14.6% YoY to INR36b (our est.: INR34.8b).
- Gross margin expanded 605bp on a YoY basis to 65.4%.
- EBITDA margin expanded 190bp on a YoY basis at 14.4% (our est.: 14.1%) as higher gross margin was offset by higher other expenses/R&D cost (up 265bp/130bp YoY as % of sales).
- EBITDA grew 32.2% YoY at INR5.2b (vs. our est. of INR4.9b).
- The exceptional item of INR1,350m in 4QFY26 pertains to 1) impairment of investments (INR747m); 2) incremental impact of change in the labor code (INR445m); and 3) gain on reversal of impairment loss (INR142.9m).
- Adj. PAT grew 48.2% YoY to INR4.5b (our est.: INR3.9b).
- For FY26, its revenue/EBITDA/PAT grew 13.5%/19.6%/17.8% YoY.

**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com) **Vipul Mehta** (vipul.mehta@motilalosal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilalosal.com/Institutional-Equities](http://www.motilalosal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

### International business drives growth; gradual revival in DF

- Domestic formulation (DF) business grew 8.9% YoY to INR23.2b. (64.5% of sales).
- International business grew 26% YoY to INR12.2b for the quarter.
- Within international business, US sales grew 26% YoY to INR7.7b (21.3% of sales).
- Other international sales grew 24% YoY to INR4.5b (12.6% of sales).

### Highlights from the management commentary

- ALKEM guided 100-150bp higher YoY growth compared to IPM in the DF segment. Overall IPM growth is getting better due to new molecules like Semaglutide, and ALKEM remains confident in further improving the growth prospects.
- ALKEM guided a higher single-digit YoY growth in the US in CC terms. This would be largely led by new launches, offsetting the base business price erosion.
- Tolvaptan generic is approved by the USFDA. ALKEM is expected to launch this in Sep'26/Oct'26. It is expected to be a limited competition product.
- ALKEM guided for higher teens YoY growth in the ROW market for FY27.
- EBITDA margin is expected to be 20%-21% for FY27
- For the EU market, Alkem has approval for prolair biosimilar as well as the Xgeva biosimilar. ALKEM has a partner to launch prolair biosimilar.
- The Occlutech deal is expected to be closed in 45-60 days.

### Quarterly performance

Y/E March	FY25				FY26				FY25	FY26	FY26E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
<b>Net Revenues</b>	<b>30,318</b>	<b>34,147</b>	<b>33,743</b>	<b>31,438</b>	<b>33,711</b>	<b>40,010</b>	<b>37,368</b>	<b>36,033</b>	<b>129,645</b>	<b>147,123</b>	<b>34,769</b>	<b>3.6</b>
YoY Change (%)	2.2	-0.7	1.5	7.1	11.2	17.2	10.7	14.6	2.3	13.5	10.6	
<b>EBITDA</b>	<b>6,086</b>	<b>7,528</b>	<b>7,594</b>	<b>3,913</b>	<b>7,391</b>	<b>9,208</b>	<b>8,280</b>	<b>5,174</b>	<b>25,121</b>	<b>30,052</b>	<b>4,902</b>	<b>5.5</b>
YoY Change (%)	56.4	0.8	7.3	-2.7	21.4	22.3	9.0	32.2	11.9	19.6	25.3	
Margins (%)	20.1	22.0	22.5	12.4	21.9	23.0	22.2	14.4	19.4	20.4	14.1	
Depreciation	805	789	853	1,125	877	936	950	1,058	3,572	3,821	938	
<b>EBIT</b>	<b>5,282</b>	<b>6,739</b>	<b>6,741</b>	<b>2,788</b>	<b>6,514</b>	<b>8,272</b>	<b>7,330</b>	<b>4,116</b>	<b>21,550</b>	<b>26,232</b>	<b>3,965</b>	
YoY Change (%)	66.7	0.2	5.7	-12.5	23.3	22.7	8.7	47.6	57.4	34.8	42.2	
Margins (%)	17.4	19.7	20.0	8.9	19.3	20.7	19.6	11.4	16.6	17.8	11.4	
Interest	291	281	360	284	298	350	421	539	1,217	1,608	320	
Other Income	1,203	1,345	930	1,460	1,365	1,037	1,431	2,001	4,937	5,834	1,200	
<b>PBT before EO Exp</b>	<b>6,194</b>	<b>7,803</b>	<b>7,311</b>	<b>3,963</b>	<b>7,581</b>	<b>8,958</b>	<b>8,340</b>	<b>5,578</b>	<b>25,270</b>	<b>30,457</b>	<b>4,845</b>	
EO Exp/(Inc)	0	0	0	0	-129	0	528	1,350	0	1,748	0	
<b>PBT after EO Exp</b>	<b>6,194</b>	<b>7,803</b>	<b>7,311</b>	<b>3,963</b>	<b>7,710</b>	<b>8,958</b>	<b>7,812</b>	<b>4,228</b>	<b>25,270</b>	<b>28,709</b>	<b>4,845</b>	
Tax	691	783	903	733	1,027	1,162	1,277	1,712	3,110	5,178	727	
Rate (%)	11.2	10.0	12.3	18.5	13.3	13.0	16.3	40.5	12.3	17.0	15.0	
<b>PAT (pre Minority Interest)</b>	<b>5,502</b>	<b>7,020</b>	<b>6,408</b>	<b>3,230</b>	<b>6,683</b>	<b>7,796</b>	<b>6,535</b>	<b>2,517</b>	<b>22,160</b>	<b>23,531</b>	<b>4,118</b>	
Minority Interest	51	133	150	172	41	145	175	152	505	513	195	
<b>Reported PAT</b>	<b>5,452</b>	<b>6,886</b>	<b>6,258</b>	<b>3,059</b>	<b>6,643</b>	<b>7,651</b>	<b>6,360</b>	<b>2,365</b>	<b>21,655</b>	<b>23,018</b>	<b>3,923</b>	
<b>Adj Net Profit</b>	<b>5,452</b>	<b>6,886</b>	<b>6,258</b>	<b>3,059</b>	<b>6,531</b>	<b>7,651</b>	<b>6,802</b>	<b>4,533</b>	<b>21,655</b>	<b>25,517</b>	<b>3,923</b>	<b>15.6</b>
YoY Change (%)	90.1	2.0	-2.6	0.6	19.8	11.1	8.7	48.2	13.5	17.8	28.3	

**Key Performance Indicators (Consolidated)**

Y/E March	FY25				FY26				FY25	FY26	FY26
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			
<b>India formulations</b>	20,223	24,610	23,649	21,355	22,650	27,660	24,959	23,245	89,837	98,514	23,704
YoY Change (%)	6.4	5.7	5.9	8.3	12.0	12.4	5.5	8.9	6.5	9.7	11.0
<b>US generics</b>	6,416	5,744	6,340	6,086	6,982	7,649	7,533	7,681	24,586	29,845	7,111
YoY Change (%)	(7.7)	(25.2)	(7.3)	(2.5)	8.8	33.2	18.8	26.2	(11.3)	21.4	16.8
<b>International (Ex-US)</b>	3,261	3,210	3,265	3,661	3,556	4,241	4,624	4,543	13,397	16,964	3,954
YoY Change (%)	2.2	12.0	(4.0)	28.2	9.0	32.1	41.6	24.1	8.8	26.6	8.0
<b>Cost Break-up</b>											
RM Cost (% of Sales)	35.5	35.3	35.7	40.7	34.7	35.0	34.1	34.6	36.7	34.6	38.0
Staff Cost (% of Sales)	19.9	17.9	18.5	19.6	20.6	17.8	19.3	19.8	18.9	19.3	20.3
R&D Expenses(% of Sales)	4.1	4.3	3.9	5.0	3.5	3.3	3.7	6.4	4.3	4.2	4.1
Other Cost (% of Sales)	20.4	20.5	19.4	22.2	19.3	21.0	20.8	24.9	20.6	21.5	23.5
Gross Margins(%)	64.5	64.7	64.3	59.3	65.3	65.0	65.9	65.4	63.3	65.4	62.0
EBITDA Margins(%)	20.1	22.0	22.5	12.4	21.9	23.0	22.2	14.4	19.4	20.4	14.1
EBIT Margins(%)	17.4	19.7	20.0	8.9	19.3	20.7	19.6	11.4	16.6	17.8	11.4




**Key highlights from the management commentary**

- ALKEM launched the GLP product (Semaglutide) in India and has garnered an 11% market share. Expect demand tailwind and ALKEM’s execution to drive promising business prospects from this product.
- R&D spending is stepped up in 4QFY26 due to increased product filings.
- Other expenses are higher for 4QFY26 due to due-diligence related cost, foreign currency impact, internal renovation related costs.
- Trade generics YoY revenue growth has been muted at 4.3% on an annualized basis. Focus has been on profitability.
- ALKEM indicated Chronic share in the Rx DF business is 22% of the Rx business, and the company is striving to increase the share going forward as well.
- ETR is expected to be 27%-29% for FY27.


**Key exhibits**

**Exhibit 1: DF revenue grew 8.9% YoY in 4QFY26**




Source: MOFSL, Company

**Exhibit 2: US sales grew 26.2% YoY in 4QFY26**



Source: MOFSL, Company

**Exhibit 3: Cumulative US ANDA filings**



Source: MOFSL, Company

**Exhibit 4: Robust ANDA pipeline**

US Filings	# Nos.
Total ANDAs filed	192
NDA's	2

Source: MOFSL, Company

**Traction in core pharma remains intact; Medtech to add growth lever in the medium term**

**DF: Chronic therapies lead growth; ALKEM outperforms in acute therapies**

- DF segment revenue grew 9.7% YoY to INR98.5b (~67.8% contribution) in FY26.
- ALKEM outperformed IPM in 6 therapies: Derma ~2x, Gastro ~1.8x, Pain ~1.7x, VMN ~1.6x, Respiratory ~1.6x and Anti-diabetic ~1.4x.
- Strong double-digit performance in Pan/Clavam/Uprise-D3, partially offset by decline in Taxim-O/A To Z Ns/Xone and subdued performance in Pipzo for Mar-26 as per IQVIA.
- Acute/Chronic segment reported growth of 10%/16.1% vs IPM, which grew by 7.7%/13.6% YoY – a 230/250bp outperformance.
- For 4QFY26, the outperformance in Anti-Diabetic/VMN/Pain/Gastro was offset by softness in Neuro/Anti-Infective therapy.
- The company remains focused on sustaining growth above industry levels in the DF segment; we estimate ALKEM to deliver ~10.8% sales CAGR in DF, scaling to ~INR120.8b over FY26-28.


**Product launches drive growth in the international business**

- International business delivered strong growth in FY26, led by robust traction in both US/Ex-US markets; the US continues to be the key contributor to international revenues.
- Ex-US markets outpaced the US in FY26, registering 26.6% YoY growth versus 21.4% YoY in the US.
- In the US markets, growth was supported by continued traction in new launches and volume. Notably, the launch of Tolvaptan is expected to support growth in 2HFY27.
- In ex-US markets, growth was broad-based across key geographies of Australia and Germany. Management remains optimistic about the ROW opportunity due to lower pricing pressure, scalable expansion, and monetization potential from biosimilar alliances.
- ALKEM filed eight ANDAs and one BLA and received 17 ANDA approvals in FY26. It launched 11 products during FY26.
- Overall, we expect ALKEM to deliver an 11% sales CAGR in the international markets to INR57.6b over FY26-28.

**Reiterate Neutral**


- We raise our earnings estimate by 3%/5% for FY27/FY28, factoring in 1) limited competition product pipeline for the US market, 2) enhanced efforts to benefit from Semaglutide opportunities, and 3) a reduction in effective tax rate estimate. We value ALKEM at 28x 12M forward earnings to arrive at our TP of INR5,840.
- The company ended FY26 on a strong note with 13.5%, 20%, and 18% YoY growth in revenue, EBITDA, and PAT, respectively. Having said this, we expect moderation in the earnings growth trajectory over the next two years due to operational costs related to biosimilars for the US market, efforts towards improving growth prospects of the Occlutech business, and a step-up in tax rate from 18% in FY26 to 27-28% in FY27.
- Considering stable earnings over FY26-28 and valuation (29x FY27E/26x FY28E earnings), we **reiterate our Neutral rating on the stock**.

**Exhibit 5: P/E chart**



Source: MOFSL, Company, Bloomberg


**Exhibit 6: EV/EBITDA chart**



Source: MOFSL, Company, Bloomberg


## Story in charts

**Exhibit 7: Total sales grew 14.6% YoY in 4QFY26**




Source: Company, MOFSL

**Exhibit 8: Gross margin up 605bp YoY in 4QFY26**




Source: Company, MOFSL

**Exhibit 9: EBITDA margin up 190bp YoY in 4QFY26**




Source: Company, MOFSL

**Exhibit 10: EPS grew 48% YoY to INR38 in 4QFY26**




Source: Company, MOFSL

**Exhibit 11: Expect 11.4% sales CAGR in the US over FY26-28**




Source: Company, MOFSL

**Exhibit 12: EBITDA margin to expand ~30bp over FY26-28**




Source: Company, MOFSL

**Exhibit 13: Expect revenue CAGR of 12% over FY26-28**




Source: Company, MOFSL

**Exhibit 14: Expect India sales CAGR of 10.8% over FY26-28**




Source: Company, MOFSL

**Exhibit 15: Return ratios expected to moderate going ahead**



Source: Company, MOFSL

**Exhibit 16: Expect earnings to stabilize over FY26-28**



Source: Company, MOFSL

## Financials and Valuations

### Consolidated – Income statement

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>Total Income from Operations</b>	<b>106,342</b>	<b>115,993</b>	<b>126,676</b>	<b>129,645</b>	<b>147,123</b>	<b>165,437</b>	<b>183,823</b>
Change (%)	20.2	9.1	9.2	2.3	13.5	12.4	11.1
<b>Total Expenditure</b>	<b>85,813</b>	<b>99,198</b>	<b>104,221</b>	<b>104,524</b>	<b>117,071</b>	<b>131,805</b>	<b>145,745</b>
<b>EBITDA</b>	<b>20,529</b>	<b>16,795</b>	<b>22,455</b>	<b>25,121</b>	<b>30,052</b>	<b>33,632</b>	<b>38,078</b>
Margin (%)	19.3	14.5	17.7	19.4	20.4	20.3	20.7
Depreciation	3,040	3,104	2,993	3,572	3,821	4,702	5,190
<b>EBIT</b>	<b>17,490</b>	<b>13,690</b>	<b>19,462</b>	<b>21,550</b>	<b>26,232</b>	<b>28,930</b>	<b>32,888</b>
Int. and Finance Charges	524	1,074	1,124	1,217	1,608	1,900	1,800
Other Income	1,627	2,161	3,108	4,937	5,834	5,042	5,299
<b>PBT bef. EO Exp.</b>	<b>18,592</b>	<b>14,778</b>	<b>21,446</b>	<b>25,270</b>	<b>30,457</b>	<b>32,072</b>	<b>36,387</b>
EO Items	-150	-1,730	-1,215	0	-1,748	0	0
<b>PBT after EO Exp.</b>	<b>18,443</b>	<b>13,048</b>	<b>20,231</b>	<b>25,270</b>	<b>28,709</b>	<b>32,072</b>	<b>36,387</b>
Current Tax	1,640	2,980	2,117	3,110	5,178	8,980	10,370
Deferred Tax	0	0	0	0	0	0	0
Tax Rate (%)	8.9	22.8	10.5	12.3	18.0	28.0	28.5
Less: Minority Interest	300	226	157	505	513	840	900
<b>Reported PAT</b>	<b>16,503</b>	<b>9,842</b>	<b>17,958</b>	<b>21,655</b>	<b>23,018</b>	<b>22,252</b>	<b>25,117</b>
<b>Adjusted PAT</b>	<b>16,516</b>	<b>12,678</b>	<b>19,091</b>	<b>21,655</b>	<b>25,517</b>	<b>22,252</b>	<b>25,117</b>
Change (%)	2.6	-23.2	50.6	13.4	17.8	-12.8	12.9
Margin (%)	15.5	10.9	15.1	16.7	17.3	13.5	13.7

### Consolidated - Balance Sheet

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	239	239	239	239	239	239	239
Total Reserves	86,140	90,214	102,882	119,610	137,962	152,421	169,745
<b>Net Worth</b>	<b>86,379</b>	<b>90,453</b>	<b>103,121</b>	<b>119,849</b>	<b>138,201</b>	<b>152,660</b>	<b>169,984</b>
Minority Interest	2,094	3,897	4,023	4,488	5,288	5,288	5,288
Deferred Tax Liabilities	0	0	0	0	151	151	151
Total Loans	26,466	13,775	14,032	13,302	20,003	20,003	20,003
<b>Capital Employed</b>	<b>114,939</b>	<b>108,125</b>	<b>121,176</b>	<b>137,638</b>	<b>163,643</b>	<b>178,102</b>	<b>195,426</b>
Gross Block	35,948	36,835	43,260	46,607	60,040	74,045	85,648
Less: Accum. Deprn.	13,077	16,181	19,174	22,745	26,566	31,268	36,458
<b>Net Fixed Assets</b>	<b>22,871</b>	<b>20,654</b>	<b>24,086</b>	<b>23,862</b>	<b>33,474</b>	<b>42,777</b>	<b>49,190</b>
Goodwill on Consolidation	6,146	4,796	4,642	4,662	5,236	5,236	5,236
Capital WIP	3,395	3,103	1,586	5,481	2,818	12,315	4,214
<b>Total Investments</b>	<b>3,710</b>	<b>6,218</b>	<b>4,838</b>	<b>18,455</b>	<b>18,688</b>	<b>18,688</b>	<b>18,688</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>91,477</b>	<b>89,770</b>	<b>105,449</b>	<b>107,070</b>	<b>130,320</b>	<b>136,017</b>	<b>160,116</b>
Inventory	30,055	26,075	26,612	29,224	33,332	37,917	41,927
Account Receivables	18,846	21,322	22,528	24,663	29,791	33,541	37,268
Cash and Bank Balance	25,786	25,786	15,694	15,631	17,329	16,640	27,675
Loans and Advances	16,790	16,587	40,616	37,552	49,868	47,920	53,245
<b>Curr. Liability &amp; Prov.</b>	<b>25,753</b>	<b>29,442</b>	<b>34,572</b>	<b>39,273</b>	<b>45,086</b>	<b>55,124</b>	<b>60,211</b>
Account Payables	11,734	11,650	17,481	18,394	22,442	23,833	26,354
Other Current Liabilities	7,955	10,370	12,824	15,906	16,326	20,297	22,553
Provisions	6,064	7,421	4,267	4,973	6,319	10,994	11,305
<b>Net Current Assets</b>	<b>65,725</b>	<b>60,329</b>	<b>70,877</b>	<b>67,797</b>	<b>85,234</b>	<b>80,892</b>	<b>99,904</b>
Deferred Tax assets	13,093	13,025	15,148	17,383	18,194	18,194	18,194
<b>Appl. of Funds</b>	<b>114,939</b>	<b>108,125</b>	<b>121,177</b>	<b>137,638</b>	<b>163,644</b>	<b>178,102</b>	<b>195,426</b>

## Financials and Valuations

### Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>Basic (INR)</b>							
<b>EPS</b>	<b>138.1</b>	<b>106.0</b>	<b>159.7</b>	<b>181.1</b>	<b>213.4</b>	<b>186.1</b>	<b>210.1</b>
Cash EPS	163.6	132.0	184.7	211.0	245.4	225.5	253.5
BV/Share	723	757	863	1,002	1,156	1,277	1,422
DPS	59.0	50.0	40.0	45.0	50.0	55.0	55.0
Payout (%)	50.7	72.0	31.6	29.4	30.8	35.0	31.0
<b>Valuation (x)</b>							
P/E	39.5	51.4	34.1	30.1	25.5	29.3	26.0
Cash P/E	33.3	41.3	29.5	25.8	22.2	24.2	21.5
P/BV	7.5	7.2	6.3	5.4	4.7	4.3	3.8
EV/Sales	6.1	5.5	5.1	5.0	4.4	4.0	3.5
EV/EBITDA	31.8	38.1	29.0	25.9	21.8	19.5	16.9
Dividend Yield (%)	1.1	0.9	0.7	0.8	0.9	1.0	1.0
FCF per share	65.5	121.5	147.3	106.9	123.5	40.2	135.8
<b>Return Ratios (%)</b>							
RoE	20.6	14.3	19.7	19.4	19.8	15.3	15.6
RoCE	17.1	11.3	18.3	18.6	18.0	14.8	15.1
RoIC	21.6	13.6	20.3	19.2	19.3	16.3	17.1
<b>Working Capital Ratios</b>							
Fixed Asset Turnover (x)	3.0	3.1	2.9	2.8	2.5	2.2	2.1
Inventory (Days)	103	82	77	82	83	84	83
Debtor (Days)	65	67	65	69	74	74	74
Creditor (Days)	40	37	50	52	56	53	52
Working Cap. Turnover (Days)	137	109	159	147	168	142	143
<b>Leverage Ratio (x)</b>							
Current Ratio	3.6	3.0	3.1	2.7	2.9	2.5	2.7
Interest Cover Ratio	33.4	12.8	17.3	17.7	16.3	15.2	18.3
Debt/Equity	0.0	-0.1	0.0	0.0	0.0	0.0	0.0

### Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	18,443	13,048	20,231	25,270	28,709	32,072	36,387
Depreciation	3,040	3,104	2,993	3,572	3,821	4,702	5,190
Interest & Finance Charges	-703	1,074	1,124	1,217	1,608	-3,142	-3,499
Direct Taxes Paid	-3,969	-2,734	-4,069	-5,040	-6,290	-8,980	-10,370
(Inc)/Dec in WC	-5,450	3,268	-516	-2,140	-4,152	3,652	-7,976
<b>CF from Operations</b>	<b>11,361</b>	<b>17,759</b>	<b>19,763</b>	<b>22,879</b>	<b>23,695</b>	<b>28,304</b>	<b>19,731</b>
<b>CF from Operating incl EO</b>	<b>11,110</b>	<b>16,825</b>	<b>19,482</b>	<b>19,128</b>	<b>19,630</b>	<b>28,304</b>	<b>19,731</b>
(Inc)/Dec in FA	-3,280	-2,297	-1,868	-6,348	-4,870	-23,502	-3,502
<b>Free Cash Flow</b>	<b>7,830</b>	<b>14,528</b>	<b>17,614</b>	<b>12,781</b>	<b>14,761</b>	<b>4,802</b>	<b>16,229</b>
(Pur)/Sale of Investments	-12,051	1,955	-10,612	-10,119	-13,025	0	0
Others	980	1,471	2,395	3,479	1,223	5,042	5,299
<b>CF from Investments</b>	<b>-14,351</b>	<b>1,128</b>	<b>-10,085</b>	<b>-12,988</b>	<b>-16,672</b>	<b>-18,460</b>	<b>1,797</b>
Inc/(Dec) in Debt	8,628	-11,408	-5,132	-1,941	1,141	0	0
Interest Paid	-401	-905	-913	-806	-1,235	-1,900	-1,800
Dividend Paid	-4,219	-5,295	-5,405	-5,046	-6,137	-7,793	-7,793
<b>CF from Fin. Activity</b>	<b>3,796</b>	<b>-16,388</b>	<b>-19,489</b>	<b>-8,110</b>	<b>-5,034</b>	<b>-10,533</b>	<b>-10,493</b>
<b>Inc/Dec of Cash</b>	<b>555</b>	<b>1,565</b>	<b>-10,093</b>	<b>-1,969</b>	<b>-2,076</b>	<b>-689</b>	<b>11,036</b>
Opening Balance	1,705	2,297	3,862	-6,231	-8,200	-10,275	-10,964
<b>Closing Cash and Cash Eq.</b>	<b>2,297</b>	<b>3,862</b>	<b>-6,231</b>	<b>-8,200</b>	<b>-10,275</b>	<b>-10,964</b>	<b>71</b>
Bank Balances	23,489	21,924	21,924	23,830	27,604	27,604	27,604
<b>Total Cash and Cash Eq.</b>	<b>25,786</b>	<b>25,786</b>	<b>15,694</b>	<b>15,630</b>	<b>17,329</b>	<b>16,640</b>	<b>27,675</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motalal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motalaloswal.com](http://www.motalaloswal.com). MOFSL (erstwhile Motalal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motalal Oswal Financial Services Limited are available on the website at <http://onlinereports.motalaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motalal Oswal Financial Services Limited are available on the website at <https://galaxy.motalaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motalal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong "SFO". As per SEBI (Research Analyst Regulations) 2014 Motalal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motalal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motalal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motalal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motalal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motalaloswal.com](mailto:grievances@motalaloswal.com).

Nainesh Rajani  
Email: [nainesh.rajani@motalaloswal.com](mailto:nainesh.rajani@motalaloswal.com)  
Contact: (+65) 8328 0276

**Specific Disclosures**

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.